By Inteledoc Expert Team | 10 min read | Dr. Naveen Satija, MBBS, FIAGES, DNB (Surgery)
The two names dominating the global conversation about medical weight loss are Ozempic and Mounjaro. Both are injectable weekly medicines. Both work through gut hormone pathways. Both have transformed outcomes for patients who struggled for years with conventional approaches. But they are not the same medicine — and choosing between them is a clinical decision, not a consumer preference. This blog gives you the complete comparison: how they differ, which patients do better on each, what access looks like in India, and how to find out which is right for you.
The Core Difference — One Hormone vs Two
Understanding why Mounjaro and Ozempic produce different results starts with a single biological fact: they work on different hormone systems.
Ozempic (semaglutide) activates one receptor — the GLP-1 receptor. GLP-1 is a gut hormone released after eating that tells your brain you are full and slows stomach emptying. Activating this receptor reduces hunger, improves blood sugar, and supports weight loss. It is an excellent medicine with over fifteen years of clinical evidence behind it.
Mounjaro (tirzepatide) activates two receptors simultaneously — GLP-1 and GIP. GIP (Glucosedependent Insulinotropic Polypeptide) is a second gut hormone that works alongside GLP-1 in regulating how the body stores and burns energy. The combination of both pathways produces a more comprehensive metabolic effect than either hormone alone — which is why tirzepatide clinical trial results consistently show greater average weight loss than semaglutide trials, across comparable patient groups.
GLP-1 receptor agonist. Once weekly injection. 0.5–1mg for diabetes; 2.4mg (Wegovy) for weight loss. Average weight loss ~15% in STEP trials. 15+ years clinical evidence. Currently more accessible in India.
Dual GLP-1 + GIP receptor agonist. Once weekly injection. 5–15mg. Average weight loss up to 20.9% in SURMOUNT trials. Strong but shorter clinical record. Premium pricing. Growing specialist access in India.
What the Clinical Trial Numbers Actually Mean in Practice
The headline numbers — 15% vs 20.9% average weight loss — are impressive, but they require context to be useful for an individual patient making a decision.
First: these are averages. Individual responses vary significantly based on biology. Some patients achieve extraordinary results on semaglutide. Some patients on tirzepatide achieve results near the trial average; others exceed it substantially. Neither medicine guarantees a specific outcome for a specific person — which is why the individualised medical assessment is the foundation of every good programme.
Second: the higher efficacy of tirzepatide comes with higher cost and, currently in India, more limited access. For many patients, semaglutide offers excellent clinical results at a more accessible price point, and is the right clinical starting choice. For patients who need maximum efficacy — very high BMI, multiple metabolic conditions, or a previous partial response to semaglutide — tirzepatide may be the more appropriate first or second step.
Third: both medicines work significantly better within a comprehensive clinical programme than as standalone prescriptions. The medicine and the programme are not separable in terms of optimal outcomes. This is why Inteledoc’s approach integrates both within a single doctor-supervised framework. See our programme plans here.
Inteledoc's doctors assess every patient individually — metabolic profile, health history, previous treatment response, clinical goals, and practical considerations including cost. The recommendation is always the most clinically appropriate medicine for that specific person, not a default to either option. Book your assessment here.
Accessing Both Medicines in India — The Honest Picture
Semaglutide in appropriate doses for weight management is accessible through specialist prescription in India at Inteledoc and other obesity medicine clinics. The process involves a proper medical assessment, prescription, and supervised programme. Tirzepatide is accessible through specialist clinics as an imported medicine under appropriate frameworks, though at higher cost and with somewhat more limited availability. Both require doctor prescription — neither should be pursued through unregulated online sources.
For patients genuinely unsure which medicine is more appropriate for their situation, the answer comes from the assessment — not from a comparison article. Read our FAQ on how Inteledoc’s assessment and prescription process works.
Side Effects — How Mounjaro and Ozempic Compare
Both medicines share a similar side effect profile, given their overlapping GLP-1 mechanism. Nausea, reduced appetite, mild fatigue, and occasional digestive changes in the early weeks are the most common experiences with both. These are predominantly dose-escalation effects — meaning they are most pronounced when the dose increases and typically resolve as the body adapts.
Tirzepatide’s additional GIP mechanism does not appear to add meaningfully to side effect burden in clinical trials — in fact, some analyses suggest tirzepatide patients report slightly lower nausea rates than semaglutide patients at comparable weight loss outcomes. Both medicines share the same contraindications around thyroid history and pancreatitis.
Frequently Asked Questions
Yes — switching is a common clinical scenario for patients who have had a partial response tosemaglutide and want to explore tirzepatide. The switch is managed by your doctor with appropriate dose timing and transition guidance to minimise disruption and optimise results.
Tirzepatide (Mounjaro) is currently more expensive than semaglutide in India, primarily because it is accessed as an imported medicine. Semaglutide in appropriate weight management doses typically costs ₹8,000–₹18,000 per month. Tirzepatide costs vary and are best confirmed at your initial consultation with your Inteledoc doctor.
Both medicines use a gradual dose escalation approach over the first several weeks. The pace of weight loss once therapeutic doses are reached appears somewhat faster with tirzepatide based on trial comparisons — but individual experience varies significantly and rapid early weight loss is not always clinically desirable.
Moderate kidney disease is not a contraindication for tirzepatide, and emerging evidence suggests potential kidney-protective benefits. Severe kidney disease requires careful clinical assessment before either semaglutide or tirzepatide is prescribed. Your doctor will review kidney function as part of the pre-treatment blood panel.
Yes — and both medicines are associated with significant improvements in non-alcoholic fatty liver disease (NAFLD) through weight loss and direct metabolic effects. Fatty liver is actually one of the conditions where GLP-1 and dual GLP-1/GIP treatment shows particularly strong ancillary benefit.
Both semaglutide and tirzepatide are administered via a small pre-filled pen injector — a subcutaneous injection just under the skin, typically in the abdomen or thigh. The needle is very fine and most patients report minimal discomfort. Your Inteledoc doctor provides full guidance on self-administration at your first prescription.
The most clinically significant interactions are with diabetes medications — particularly sulphonylureas and insulin — where dose adjustments may be needed as blood sugar improves. A comprehensive medication review is part of every Inteledoc initial assessment, and all interactions are managed proactively by your doctor.
Not currently for the weight management formulations. Generic versions of some diabetes-dose semaglutide formulations exist in India, but their quality and dosing for weight management purposes vary. Your doctor will advise on the most appropriate and reliably sourced formulation for your programme.
A medical assessment is the only reliable way to answer this. Your metabolic profile, insulin resistance level, previous treatment history, BMI, and health conditions together determine which medicine’s mechanism is most appropriate for your biology. Book an Inteledoc assessment to find out.
Ready to start your doctor-supervised weight loss journey?
Inteledoc — India's first metabolonomics-based weight loss programme. Online & in-person in Gurugram. Plans from ₹1,500/month.
Book a consultation